Akèy › Kansè pwostat › Illinois › Chicago
Etid klinik pou Kansè pwostat nan Chicago, IL
45 etid pou Kansè pwostat ap chèche patisipan nan sit nan ak bò kote Chicago (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Ap rekriteFaz 3
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Ap rekriteFaz 3
- Northwestern University, Chicago
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- University of Chicago Hospital, Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- ak 1 plis
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- University of Illinois Cancer Center, Chicago
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Ap rekriteFaz 2
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Ap rekriteFaz 2/3
- University of Chicago, Chicago
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Ap rekriteFaz 3
- University of Illinois Chicago, Chicago
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Ap rekriteFaz 3
- Northwestern University, Chicago
- University of Illinois Cancer Center at Chicago, Chicago
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Ap rekriteFaz 3
- Research Site, Chicago
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Ap rekriteFaz 3
- Rush University Medical Center-Hematology and Oncology ( Site 0028), Chicago
- University of Illinois at Chicago-University of Illinois Cancer Center ( Site 0063), Chicago
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Ap rekriteFaz 3
- Northwestern University, Chicago
- University of Illinois, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Ap rekriteFaz 1
- University of Illinois Hospital & Health Sciences System, Chicago
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
Ap rekrite
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
Ap rekriteFaz 2
- University of Chicago Comprehensive Cancer Center, Chicago
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
Ap rekriteFaz 2
- Jesse Brown VA Medical Center, Chicago, IL, Chicago
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Ap rekriteFaz 1/2
- University of Chicago, Chicago
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Ap rekriteFaz 3
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Ap rekriteFaz 1
- University of Chicago Medical Center, Chicago
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- Research Site, Chicago
PSMA PET Combined With MRI for the Detection of PCa
Ap rekriteFaz 3Volontè an sante akeyi
- UroPartners,LLC, Chicago
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
Ap rekriteFaz 3
- Rush MD Anderson, Chicago
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Ap rekriteFaz 3
- University of Illinois, Chicago
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
Ap rekriteFaz 2
- Northwestern University, Chicago
rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
Ap rekriteFaz 1 bonèVolontè an sante akeyi
- Northwestern University, Chicago
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
Ap rekriteFaz 2
- UChicago Medicine Comprehensive Cancer Center, Chicago
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Ap rekriteEtid obsèvasyon
- University of Illinois at Chicago, Chicago
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- University of Chicago, Chicago
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Northwestern, Chicago
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1
- Research Site, Chicago
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1/2
- Rush University, Chicago
Clinical Trial of Approaches to Prostate Cancer Surgery
Ap rekrite
- Northwestern University, Chicago
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
Ap rekriteFaz 2
- Northwestern University, Chicago
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1/2
- University of Chicago Medical Center, Chicago
Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life
Ap rekrite
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
GU-01: Glycyrrhizin in Prostate Cancer
Ap rekriteFaz 2
- University of Illinois, Chicago
PSMA PET for Surveillance After Focal Therapy
Ap rekrite
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- The University of Chicago Comprehensive Cancer Center, Chicago
Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)
Ap rekriteEtid obsèvasyon
- The University of Chicago, Hyde Park · 5 mi lwen
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
Ap rekriteFaz 3
- Northwestern University, Chicago
- University of Illinois, Chicago
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
Ap rekriteFaz 4
- University of Chicago Medical Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Chicago
Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
Ap rekrite
- The University of Illinois at Chicago (UIC), Chicago
- UChicago Medicine Comprehensive Cancer Center, Chicago
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Ap rekriteFaz 3
- Rush University Medical Center, Chicago
- University of Illinois, Chicago
Geriatric Assessment and Technology Evaluation in Prostate Cancer
Ap rekriteEtid obsèvasyon
- o University of Chicago Medicine Comprehensive Cancer Center, Chicago
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
Ap rekriteFaz 4
- University of Chicago Medical Center, Chicago
Etid Kansè pwostat nan lòt vil
- New York City, NY103 etid
- Houston, TX76 etid
- Los Angeles, CA61 etid
- Boston, MA59 etid
- St. Louis, MO46 etid
- San Francisco, CA45 etid
- Philadelphia, PA44 etid
- Baltimore, MD43 etid
- Nashville, TN42 etid
- Seattle, WA42 etid
- Washington, DC38 etid
- Dallas, TX36 etid
Lòt etid nan Chicago
- Kansè Poumon ki pa ti selil61 etid
- Kansè nan tete58 etid
- Kansè (tout kalite)51 etid
- Kansè Metastatik45 etid
- Obèsite41 etid
- Kansè poumon41 etid
- Kansè ovè36 etid
- Akidan serebavaskilè34 etid
- Kansè kolorektal33 etid
- Ensifizyans kadyak31 etid
- Sipwa28 etid
- Karsinòm selil skuamèz tèt ak kou26 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.